132294-16-7

Usage

Uses

Intermediate in the preparation of carbocyclic nucleoside derivatives.

Upstream product

• 127696-10-0 trans-3,3-diethoxy-1,2-cyclobutanedicarboxylic acid diethyl ester 
• 132178-71-3 trans-3,3-diethoxy-1,2-cyclobutanedicarboxylic acid 
• 138736-91-1 (1S,2R)-3,3-Dimethoxy-cyclobutane-1,2-dicarboxylic acid bis-((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl) ester 
• 138736-92-2 (2S,3R)-(+)-bis[hydroxymethyl]-1,1-dimethoxycyclobutane 
• 138736-93-3 C₂₂H₂₄O₆ 
• 132294-15-6 (1S-trans)-3,3-diethoxy-1,2-cyclobutanedimethanol dibenzoate ester 
• 126261-70-9 (+/-)-trans-1,2-bis-(3,3-diethoxycyclobutylen)methanol 
• 15210-38-5 (trans)-3,3-diethoxy-1,2-cyclobutanedicarboxylic acid,diethyl ester 
• 124770-79-2 C₂₄H₂₈O₆ 
• 124770-79-2 C₂₄H₂₈O₆ 
• 98-88-4 benzoyl chloride 
• 104-15-4 toluene-4-sulfonic acid 
• 132178-72-4 <1S-<1α(S^*),2β(S^*)>>-3,3-diethoxy-N,N'-bis-(2-hydroxy-1-phenylethyl)-1,2-cyclobutanedicarboxamide 
• 132294-14-5 (1S-trans)-3,3-diethoxy-1,2-cyclobutanedimethanol 

Downstream Products

• 1576-92-7 (E)-1,4-dibenzoyloxy-2-butene 
• 55759-12-1 cis-1,4-dibenzoyloxybut-2-ene 
• 126261-73-2 C₂₀H₂₀O₅ 
• 124794-61-2 C₂₅H₃₃ClN₄O₄ 
• 124794-61-2 C₂₅H₃₃ClN₄O₄ 
• 124770-84-9 C₂₅H₃₅N₅O₄ 
• 124770-84-9 C₂₅H₃₅N₅O₄ 
• 124770-82-7 (1,2-trans)-1-amino-2,3-bis(cyclohexylcarbonyloxymethyl)cyclobutane 
• 124770-82-7 (1,2-cis)-1-amino-2,3-bis(cyclohexylcarbonyloxymethyl)cyclobutane 
• 124770-85-0 cis-trans-9-<2,3-bis-(hydroxymethyl)cyclobutyl>adenine 
• 124770-83-8 1-(cyclohexylcarbonyl)amino-3-(cyclohexylcarbonyloxy)methyl-2-cyclobutanemethanol 
• 124770-85-0 (+/-)-9-<(1β,2α,3β)-2,3-bis(hydroxymethyl)-1-cyclobutyl>adenine 

Relevant academic research and scientific papers

A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist

We describe a stereodefined synthesis of the newly identified non-natural phosphorothioate cyclic dinucleotide (CDN) STING agonist, BMT-390025. The new route avoids the low-yielding racemic approach using P(III)-based reagents, and the stereospecific assembly of the phosphorothioate linkages are forged via the recently invented P(V)-based platform of the so-called PSI (Ψ) reagent system. This P(V) approach allows for the complete control of chirality of the P-based linkages and enabled conclusive evidence of the absolute configuration. The new approach offers robust procedures for preparing the stereodefined CDN in eight steps starting from advanced nucelosides, with late-stage direct drop isolations and telescoped steps enabling an efficient scale-up that proceeded in an overall 15% yield to produce multigram amounts of the CDN.

CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS

Described herein are cyclobutyl nucleoside analogs of Formula (I), pharmaceutical compositions that include one or more cyclobutyl nucleoside analogs and methods of using the same to treat HBV, HDV and/or HIV.

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Method for epoxidation of 3-methylenecyclopropanes

The present invention provides a process for the expoxidation of a protected 3-methylene-(trans)-1,2,-hydroxymethylcyclopropane with cyclohexanone and potassium peroxymonosulfate and subsequent rearrangement to provide the corresponding cyclobutanone.

Process for the preparation of an antiviral agent

(1R,trans) Diprotected 3-methylene-1,2-cyclopropanedimethanol is oxidized to an optically active diol STR1 which is then cyclized to an orthoester STR2 This orthoester is then treated with a Lewis acid catalyst to give the cyclobutanone STR3 which is useful as an intermediate in the preparation of the antiviral agent ?1R-(1α,2β,3α)!-2-amino-9-?2,3-bis(hydroxymethyl)cyclobutyl!-1,9-dihydro-6H-purin-6-one.

Bis (hydroxymethyl) cyclobutyl purines

Antiviral activity is exhibited by compounds having the formula STR1 and its pharmaceutically acceptable salts wherein R1 is STR2 wherein R2 is hydrogen, methyl, fluoro, chloro, bromo, iodo, hydroxy or amino; or trifluoromethyl; Rsu

A novel approach toward the synthesis of chiral 2,3-dideoxy nucleosides and their carbocyclic analogues

Photochemical ring-expansion of chiral 2(S),3(R)-bis [(benzoyloxy)methyl]cyclobutanone (3) in the presence of alcohols and acidic N-H functional groups gives anomeric mixtures of acetals and N-amino acetals, respectively, with retention of stereochemistry

Optically active cyclobutyl pyrimidine

The compound of the formula STR1 [1R-(1α(E),2β,3α)]-1-[2,3-bis(hydroxymethyl)cyclobutyl]-5-(2-bromoethenyl)-2,4(1H,3H)-pyrimidinedione, is an antiviral agent that is active against herpes simplex virus 1 and varicella-zoster virus.

Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside

A novel process and intermediates are disclosed for the preparation of the optically active compound STR1 wherein R3 is a protecting group. This cyclobutanone compound is used to prepare a compound of the formula STR2 having anti-viral activity.

An efficient and diastereoselective [2+2] cycloaddition: Convenient and enantioselective route to trans-2',3'-dihydroxymethylcyclobutane nucleoside analogs

An efficient route to (2S-trans)-2,3-bis[(benzoyloxy)methyl]cyclobutanone (3a), a key intermediate in the synthesis of cyclobutane nucleoside analogs, via a novel asymmetric [2+2] cycloaddition, is described.